The first fully A.I.-generated drug enters clinical trials in human patients
[ad_1] Alex Zhavoronkov, left, founder and CEO of Insilico Medicine, and Feng Ren, co-CEO and chief scientific officer, at the company’s robotics lab in Suzhou, China. Source: Insilico Medicine The first drug fully generated by artificial intelligence entered clinical trials with human patients this week. Insilico Medicine, a Hong Kong-based biotech startup with more than…